Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 53Colorectal Neoplasms 42Neoplasms 37Lung Neoplasms 22Breast Neoplasms 15Colonic Neoplasms 14Colonic Polyps 13Rare Diseases 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Ovarian Neoplasms 7Adenoma 7Pulmonary Disease, Chronic Obstructive 6Neoplasm Metastasis 6Heart Failure 6Head and Neck Neoplasms 6Rectal Neoplasms 5Motor Activity 5Liver Neoplasms 5Fibrosis 5Carcinoma, Squamous Cell 5Barrett Esophagus 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Neoplasms by Site 4Mental Disorders 4Lymphoma 4Lung Diseases 4Leukemia 4Esophageal Neoplasms 4

Interventions

Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Bronchiolitis Obliterans × Clear all
NCT00029328 2015-03-25

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

FDA Office of Orphan Products Development

Phase 1/2 Completed
15 enrolled

Bronchiolitis Obliterans, Pneumonia, Respiratory Distress Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡